The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats
Abstract
Kupffer cells (KC) play an important role in the pathogenesis of inflammatory liver diseases leading to fibrosis. Anti-inflammatory drugs are only effective when administered at high doses that may cause side effects. Therefore, dexamethasone coupled to mannosylated albumin (Dexa(5)-Man(10)-HSA) was designed by us to selectively deliver this anti-inflammatory drug to the KC. The effectiveness of Dexa(5)-Man(10)-HSA was studied both in organ cultures and fibrosis induced by bile duct ligation (BDL) in rats. Dexa(5)-Man(10)-HSA accumulated in livers of both healthy and fibrotic rats (67% +/- 5% and 70% +/- 9% of the dose, respectively) and uptake was found almost exclusively in KC. Active dexamethasone was liberated from its carrier, because Dexa(5)-Man(10)-HSA could effectively inhibit nitric oxide (NO) and tumor necrosis factor alpha (TNF-alpha) release in endotoxin-activated liver slices. In vivo, however, this was associated with increased collagen I and III depositions and enhanced tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA expression. This was accompanied by a decreased influx of reactive oxygen species (ROS) producing cells in the livers of BDL animals treated with Dexa(5)-Man(10)-HSA as compared with untreated BDL rats. Dexa(5)-Man(10)-HSA treatment also replenished the depleted glycogen stores in hepatocytes of BDL livers. In conclusion, our studies showed selective delivery of dexamethasone to KC with Dexa(5)-Man(10)-HSA. This conjugate reduced intrahepatic ROS in vivo and TNF-alpha production in vitro and prevented glycogen depletion in vivo, indicating effective pharmacologic targeting. Dexa(5)-Man(10)-HSA, however, also accelerated fibrogenesis, which was paralleled by TIMP-1 mRNA induction. Targeting of dexamethasone to KC provides evidence for a dual role of this cell type in fibrogenesis of BDL rats.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, other studies in rat models failed to demonstrate comparable anti-fibrotic effects and instead reported increased collagen deposition despite effective suppression of inflammatory signaling (161)”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [161]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
Chomczyński, P. (1993) · PubMed · Cited by 2,788
The Liver: Biology and Pathobiology.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-690_3 · Cited by 1,615
The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens
Underhill, D. M., Ozinsky, A., Hajjar, A. M., Stevens, A. M., Wilson, C. B., Bassetti, M., & Aderem, A. A. (1999) · Nature · doi:10.1038/44605 · Cited by 1,370
Nitrite and nitrate determinations in plasma: a critical evaluation
Moshage, H. J., Kok, B., Huizenga, J. R., & Jansen, P. L. M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.892 · Cited by 1,094
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
The mannose receptor is a pattern recognition receptor involved in host defense
Stahl, P. D., & Ezekowitz, R. A. B. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80031-9 · Cited by 630
Bissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118055 · Cited by 419
Friedman, S. L. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007105 · Cited by 348
Frank, S., Madlener, M., & Werner, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.10188 · Cited by 345
Cited by
Sorted by citations
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,217
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
Targeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Role of Kupffer cells in the pathogenesis of liver disease
Kolios, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i46.7413 · Cited by 505
Liver inflammation abrogates immunological tolerance induced by Kupffer cells
Heymann, F., Peusquens, J., Ludwig‐Portugall, I., Kohlhepp, M. S., Ergen, C., Niemietz, P. M., Martin, C., van Rooijen, N., Ochando, J., Randolph, G. J., et al. (2015) · Hepatology · doi:10.1002/hep.27793 · Cited by 415
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Czaja, A. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2515 · Cited by 359
PDGF and signal transduction in hepatic stellate cells
Pinzani, M. (2002) · Frontiers in bioscience · doi:10.2741/a875 · Cited by 239
Current status of novel antifibrotic therapies in patients with chronic liver disease
Cohen‐Naftaly, M., & Friedman, S. L. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11413002 · Cited by 187
Dong, B., Zhou, Y., Wang, W., Scott, J., Kim, K., Sun, Z., Guo, Q., Yang, L., Gonzales, N. M., Wu, H., et al. (2019) · Hepatology · doi:10.1002/hep.30937 · Cited by 190
Nonalcoholic steatohepatitis: what we know in the new millennium
Harrison, S. A., Kadakia, S. C., Lang, K. A., & Schenker, S. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.07069.x · Cited by 185
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
Self-citationGraversen, J. H., Svendsen, P., Dagnæs‐Hansen, F., Dal, J., Anton, G., Etzerodt, A., Petersen, M. D., Christensen, P. A., Møller, H. J., & Moestrup, S. K. (2012) · Molecular Therapy · doi:10.1038/mt.2012.103 · Cited by 150
Bartneck, M., Scheyda, K. M., Warzecha, K. T., Rizzo, L. Y., Hittatiya, K., Luedde, T., Storm, G., Trautwein, C., Lammers, T., & Tacke, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.030 · Cited by 141
Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.
Bartneck, M., Warzecha, K. T., & Tacke, F. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.11.02 · Cited by 146
Nanoparticles for the treatment of liver fibrosis
Surendran, S. P., Thomas, R. G., Moon, M. J., & Jeong, Y. Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s145951 · Cited by 145
Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy
Lamichhane, S., & Lee, S. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01204-7 · Cited by 133
Ito, T., Fraser, I. P., Yeo, Y., Highley, C. B., Bellas, E., & Kohane, D. S. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.12.012 · Cited by 129
Molecular Pathways: Targeting the Microenvironment of Liver Metastases
Milette, S., Sicklick, J. K., Lowy, A. M., & Brodt, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1636 · Cited by 121
Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance
Mishra, N., Yadav, N. P., Kumar, V., Sinha, P., Yadav, K. S., Jain, S., & Arora, S. (2013) · BioMed Research International · doi:10.1155/2013/382184 · Cited by 120
Kupffer Cells Abrogate Cholestatic Liver Injury in Mice
Gehring, S., Dickson, E. M., Martin, M. E. S., van Rooijen, N., Papa, E. F., Harty, M. W., Tracy, T. F., & Gregory, S. H. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.015 · Cited by 117
Sugimoto, R., Enjoji, M., Kohjima, M., Tsuruta, S., Fukushima, M., Iwao, M., Sonta, T., Kotoh, K., Inoguchi, T., & Nakamuta, M. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01130.x · Cited by 115
Clinical Advancements in the Targeted Therapies against Liver Fibrosis
Bansal, R., Nagórniewicz, B., & Prakash, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/7629724 · Cited by 110
Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis
Zhou, J.-E., Sun, L., Liu, L., Jia, Y., Han, Y., Shao, J., Wang, J., Wang, Y., Yu, L., & Yan, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.038 · Cited by 104
Svendsen, P., Graversen, J. H., Etzerodt, A., Hager, H., Røge, R., Grønbæk, H., Christensen, E. I., Møller, H. J., Vilstrup, H., & Moestrup, S. K. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.004 · Cited by 84
Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats
Dang, S. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i4.557 · Cited by 85
Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance
Roohani, S., & Tacke, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147249 · Cited by 79
Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis
Beljaars, L. (2002) · Frontiers in bioscience · doi:10.2741/a917 · Cited by 75
Rat Hepatocyte Aquaporin–8 Water Channels Are Down–Regulated in Extrahepatic Cholestasis
Carreras, F. I., Gradilone, S. A., Mazzone, A., Garcı́a, F., Huang, B. Q., Ochoa, E. J., Tietz, P. S., LaRusso, N. F., Calamita, G., & Marinelli, R. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50170 · Cited by 71
Liver cell-targeted delivery of therapeutic molecules
Kang, J., Toita, R., & Murata, M. (2014) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2014.930017 · Cited by 62
Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma
Liu, K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i9.1946 · Cited by 60
Wang, L., Xu, J., Xue, P., Liu, J., Luo, L.-Z., Zhuge, D., Yao, Q., Li, X., Zhao, Y., & Xu, H. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129221 · Cited by 57
Bolkenius, U., Hahn, D., Gressner, A. M., Breitkopf, K., Dooley, S., & Wickert, L. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.164 · Cited by 54
Glucocorticoids as Regulators of Macrophage-Mediated Tissue Homeostasis
Díaz-Jiménez, D., Kolb, J. P., & Cidlowski, J. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669891 · Cited by 60
Macrophages as key regulators of liver health and disease
Papachristoforou, E., & Ramachandran, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.006 · Cited by 56
Violatto, M. B., Casarin, E., Talamini, L., Russo, L., Baldan, S., Tondello, C., Messmer, M., Hintermann, E., Rossi, A., Passoni, A., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b09655 · Cited by 52
Hellberg, L., Samavedam, U. K. S. R. L., Holdorf, K., Hänsel, M., Recke, A., Beckmann, T., Steinhorst, K., Boehncke, W., Kirchner, T., Möckel, N., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.91 · Cited by 48
Evaluation of fibrosis in precision-cut tissue slices
Westra, I. M., Pham, B. T., Groothuis, G. M. M., & Olinga, P. (2012) · Xenobiotica · doi:10.3109/00498254.2012.723151 · Cited by 50
Self-citationPGE2-treated macrophages inhibit development of allergic lung inflammation in mice
Draijer, C., Boorsma, C. E., Reker‐Smit, C., Post, E., Poelstra, K., & Melgert, B. N. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mab1115-505r · Cited by 47
Self-citationSelimović, D., El‐Khattouti, A., Ghozlan, H. A., Haïkel, Y., Abdel-Kader, O., & Hassan, M. (2012) · World Journal of Hepatology · doi:10.4254/wjh.v4.i12.342 · Cited by 46
The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung
Florez‐Sampedro, L., Song, S., & Melgert, B. N. (2018) · Regeneration · doi:10.1002/reg2.97 · Cited by 46
Self-citationAdapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
Hundertmark, J., Krenkel, O., & Tacke, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02418 · Cited by 46
Glucocorticoids have opposing effects on liver fibrosis in hepatic stellate and immune cells
Kim, K. H., Lee, J. M., Zhou, Y., Harpavat, S., & Moore, D. D. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1029 · Cited by 41
Review on Targeted Drug Delivery Carriers Used in Nanobiomedical Applications
Dunuweera, S. P., Rajapakse, S., Rajapakshe, D., Wijekoon, S. H. D. P., Thilakarathna, M. G. G. S. N., & Rajapakse, S. (2018) · Current Nanoscience · doi:10.2174/1573413714666181106114247 · Cited by 40
Mechanism of Hepatic Heme Oxygenase-1 Induction by Isoflurane
Hoetzel, A., Leitz, D., Schmidt, R., Tritschler, E., Bauer, I., Loop, T., Humar, M., Geiger, K. K., & Pannen, B. H. J. (2005) · Anesthesiology · doi:10.1097/00000542-200601000-00016 · Cited by 39
Production of Pro- and Anti-fibrotic Agents by Rat Kupffer Cells; The Effect of Octreotide
Xidakis, C., Ljumovic, D., Manousou, P., Notas, G., Valatas, V., Kolios, G. C., & Kouroumalis, E. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2668-8 · Cited by 39
Defying death: the hepatocyte's survival kit
Schoemaker, M. H., & Moshage, H. J. (2004) · Clinical Science · doi:10.1042/cs20040090 · Cited by 37
Chinese herb Radix Polygoni Multiflori as a therapeutic drug for liver cirrhosis in mice
Huang, C., Horng, L., Chen, C., & Wu, R.-T. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.07.034 · Cited by 36
Macrophages as a Cell-Based Therapy for Liver Disease
Starkey Lewis, P. J., Moroni, F., & Forbes, S. J. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1688502 · Cited by 36
Jiang, S., Prozeller, D., Pereira, J., Simon, J., Han, S., Wirsching, S., Fichter, M., Mottola, M., Lieberwirth, I., Morsbach, S., et al. (2019) · Nanoscale · doi:10.1039/c9nr09879h · Cited by 35
Glucocorticosteroids as antioxidants in treatment of asthma and COPD
Sadowska, A. M., Klebe, B., Germonpré, P. R., & Backer, W. A. D. (2006) · Steroids · doi:10.1016/j.steroids.2006.10.007 · Cited by 35
Site-specific drug delivery, targeting, and gene therapy
Shukla, T., Upmanyu, N., Pandey, S. P., & Sudheesh, M. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816200-2.00013-x · Cited by 36
Fichter, M., Baier, G., Dedters, M., Pretsch, L., Pietrzak-Nguyen, A., Landfester, K., & Gehring, S. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.05.005 · Cited by 33
Bahçecioğlu, İ. H., Yalnız, M., İlhan, N., Ataseven, H., & Özercan, İ. H. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2004.00312.x · Cited by 32
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 32
Unagolla, J. M., Das, S., Flanagan, R., Oehler, M., & Menon, J. U. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124381 · Cited by 31
Dose-related effects of dexamethasone on liver damage due to bile duct ligation in rats
Eken, H. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i33.5379 · Cited by 30
Xu, G. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i24.3621 · Cited by 30
Ergen, C., Niemietz, P. M., Heymann, F., Baues, M., Gremse, F., Pola, R., van Bloois, L., Storm, G., Kiessling, F., Trautwein, C., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.025 · Cited by 27
Drug Trafficking into Macrophages via the Endocytotic Receptor CD163
Graversen, J. H., & Moestrup, S. K. (2015) · Membranes · doi:10.3390/membranes5020228 · Cited by 26
Melgert, B. N., Weert, B., Schellekens, H., Meijer, D. K. F., & Poelstra, K. (2003) · Journal of drug targeting · doi:10.1080/1061186031000072969 · Cited by 26
Self-citationHori, Y., Sato, S., Yamate, J., & Kurasaki, M. (2009) · European Journal of Histochemistry · doi:10.4081/842 · Cited by 24
Schippers, M., Beljaars, L., Post, E., Lotersztajn, S., Reker‐Smit, C., Han, B., Muñoz-LLancao, P., Schmidt, M., & Poelstra, K. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241646 · Cited by 22
Self-citationMetalloproteinases in liver fibrosis: current insights
Zbodakova, O., Chalupský, K., Turečková, J., & Sedláček, R. (2017) · Metalloproteinases In Medicine · doi:10.2147/mnm.s124363 · Cited by 22
Future therapy of portal hypertension in liver cirrhosis – a guess
Sauerbruch, T., & Trebicka, J. (2014) · F1000Prime Reports · doi:10.12703/p6-95 · Cited by 21
Orbach, S. M., Ehrich, M. F., & Rajagopalan, P. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.05.006 · Cited by 20
Medina‐Montano, C., Berti, I. R., Gambaro, R. C., Limeres, M. J., Svensson, M., Padula, G., Chain, C. Y., Cisneros, J. S., Castro, G. R., Grabbe, S., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081611 · Cited by 19
Lu, J., Hsia, K., Lin, C., Chen, C., Yang, H., & Lin, M.-H. (2019) · Nutrients · doi:10.3390/nu11092224 · Cited by 18
Transcriptional activation of an anti-oxidant mouse Pon2 gene by dexamethasone
Lim, J.-A., & Kim, S. H. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.7.421 · Cited by 18
Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy
Douglass, A., Wallace, K., Koruth, M., Barelle, C. J., Porter, A. J., & Wright, M. C. (2008) · Hepatology International · doi:10.1007/s12072-008-9093-y · Cited by 17
Salvati, A. L., & Poelstra, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010217 · Cited by 16
Self-citationPoelstra, K., Beljaars, L., & Melgert, B. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.013 · Cited by 16
Self-citationDias, M. V., Castro, A. P., Campos, C. C., Silva, T. G. D. S. E., Gonçalves, R. V., Souza, R. L. M., Marques, M. J., & Novaes, R. D. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.032 · Cited by 16
Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis
Bartneck, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.009 · Cited by 14
Petrillo, T. R., Claudiano, G. D. S., Yunis‐Aguinaga, J., Manrique, W. G., de Castro, M. P., Belo, M. A. D. A., de Moraes, J. R. E., & de Moraes, F. R. (2017) · Bioscience Journal · doi:10.14393/bj-v33n4a2017-33016 · Cited by 14
Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy
Cacicedo, M. L., Medina‐Montano, C., Kaps, L., Kappel, C., Gehring, S., & Bros, M. (2020) · Cells · doi:10.3390/cells9091985 · Cited by 14
Zárybnický, T., Matoušková, P., Ambrož, M., Šubrt, Z., Skálová, L., & Boušová, I. (2019) · Genes · doi:10.3390/genes10100763 · Cited by 13
Hsieh, C., Wang, P., Lee, S.-Y., Huang, C., Chang, N., Chen, C.-M., Wu, C.-L., Wang, H.-C., & Chuang, J. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.05.039 · Cited by 13
Ki, S. H., Choi, D. W., Kim, C. W., & Kim, S. G. (2005) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.01.008 · Cited by 13
Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis
Setyawati, D. R., Sekaringtyas, F. C., Pratiwi, R. D., Rosyidah, A., Azhar, R., Gustini, N., Syahputra, G., Rosidah, I., Mardliyati, E., Tarwadi, et al. (2024) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.15.89 · Cited by 14
Stefano, J. T., Cogliati, B., dos Santos, F. M., de Lima, V. M. R., Mazo, D. F. D. C., Matte, Ú. D. S., Álvares‐da‐Silva, M. R., da Silveira, T. R., Carrilho, F. J., & de Oliveira, C. P. M. S. (2011) · Nitric Oxide · doi:10.1016/j.niox.2011.07.001 · Cited by 12
Lee, C., Bak, J., Yoon, S., & Moon, J. (2021) · Antioxidants · doi:10.3390/antiox10030366 · Cited by 12
Biodistribution of polymer hydrogel capsules for the delivery of therapeutics
Hinton, T. M., Monaghan, P., Green, D., Kooijmans, S. A. A., Shi, S., Breheney, K., Tizard, M. L., Nicolazzo, J. A., Zelikin, A. N., & Wark, K. L. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.05.028 · Cited by 12
Plasmodium yoelii: Influence of immune modulators on the development of the liver stage
Xu, W., Wang, X., Jie, Q., Jian-hua, D., & Fusheng, H. (2010) · Experimental Parasitology · doi:10.1016/j.exppara.2010.05.005 · Cited by 12
General sites of nanoparticle biodistribution as a novel opportunity for nanomedicine
Fleischmann, D., & Göpferich, A. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.027 · Cited by 12
Sharef, A., Hamdi, B. A., & Alnajar, Z. (2020) · Zanco Journal of Medical Sciences · doi:10.15218/zjms.2020.028 · Cited by 10
Advances and challenges in immunosuppressive antibody drug conjugates
Yaseen, A. A., & Tumey, L. N. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117576 · Cited by 9
Relationship between Kuppfer cells, inflammation, and fibrosis in chronic hepatitis B and C.
Stănculeţ, N., Grigoraş, A., Avădănei, E. R., Floarea-Strat, A., Amălinei, C., & Căruntu, I.-D. (2013) · The Medical-Surgical Journal · Cited by 9
Albumin–drug conjugates in the treatment of hepatic disorders
FIUME, L., Manerba, M., & Stefano, G. D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.913567 · Cited by 9
Shao, F., Ci, L., Shi, J., Fang, F., Yan, B., Liu, X., Yao, X., Zhang, M., Yang, H., Wang, Z., et al. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022143 · Cited by 8
Hada, N., Kuramochi, M., Izawa, T., Kuwamura, M., & Yamate, J. (2020) · Journal of Toxicologic Pathology · doi:10.1293/tox.2020-0016 · Cited by 7
Suzuki, K., Kanabayashi, T., Nakayama, H., & Doi, K. (2003) · Experimental and Toxicologic Pathology · doi:10.1078/0940-2993-00314 · Cited by 5
Štupica, G. T., Šoštarič, M., Jenko, M., & Podbregar, M. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.12.035 · Cited by 4
Falahatkar, B., Abdollahpour, H., & Jafari, N. (2022) · Journal of Applied Ichthyology · doi:10.1111/jai.14321 · Cited by 4
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Research progress of knee fibrosis after anterior cruciate ligament reconstruction
Liang, Y., Zhang, Q., & Fan, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1493155 · Cited by 2
Tăbăran, F., Cătoi, C., Mocan, T., MOCAN, L. C., Biris, A. R., Simon, S., Nagy, A., Taulescu, M. A., Bolfă, P., & Cătoi, A. F. (2013) · Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Veterinary Medicine · doi:10.15835/buasvmcn-vm:70:1:9578 · Cited by 1
Bartneck, M., & Tacke, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-45433-7_11 · Cited by 1
Metadata
- Authors
- Melgert, B. N., Olinga, P., Van Der Laan, J. M. S., Weert, B., Cho, J., Schuppan, D., Groothuis, G. M. M., Meijer, D. K. F., & Poelstra, K.
- Affiliations
- University of Groningen (NL)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Melgert, Barbro N.
- Weert, Betty
- Venue
- Hepatology
- Published
- 2001-10
- Volume
- 34
- Issue
- 4
- Pages
- 719-728
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2158299509
- Cited by
- 115
- References
- 52
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 2 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- Kupffer cells, dexamethasone, targeted drug delivery, liver fibrosis, bile duct ligation, liver inflammation, nitric oxide, TNF-α, reactive oxygen species, TIMP-1, glycogen depletion, hepatocytes, collagen deposition
- MeSH terms
- Animals, Collagen, Dexamethasone, Hepatitis, Kupffer Cells, Liver Cirrhosis, Experimental, Liver Glycogen, Male, Nitric Oxide, Serum Albumin, Tumor Necrosis Factor-alpha, Interleukin-10, Rats, Wistar, Tissue Inhibitor of Metalloproteinase-1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review